We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Down 12.3% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for CVS Health (CVS - Free Report) . Shares have lost about 12.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is CVS Health due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
CVS Health Q2 Earnings Surpass Estimates, Margins Up
CVS Health second-quarter 2023 adjusted earnings per share of $2.21 declined 12.6% year over year but exceeded the Zacks Consensus Estimate by 4.3%.
The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale, and other adjustments.
On a reported basis, the company’s GAAP earnings were $1.48 per share, down 35.4% year over year.
Total revenues in the second quarter rose 10.3% year over year to $88.92 billion. The top line also beat the Zacks Consensus Estimate by 2.5%.
Quarter in Detail
The company recently realigned the composition of its segments. It created the Health Services segment (comprising the company’s pharmacy benefit management operations, health care services and provider enablement solutions) and the Pharmacy & Consumer Wellness segment (comprising enterprise pharmacy fulfilment and retail front store operations).
Health Services revenues were up 7.6% to $46.22 billion in the reported quarter. The upside was primarily driven by pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health, partially offset by continued client price improvements.
Total pharmacy claims processed fell 1.2% on a 30-day equivalent basis, reflecting an expected Medicaid customer contract change and a decrease in COVID-19 vaccinations. The decline was largely offset by net new business.
Revenues from CVS Health’s Pharmacy & Consumer Wellness segment were up 7.6% year over year to $28.78 billion. The impressive growth was driven by increased prescription and front store volume, pharmacy drug mix and brand inflation. However, this growth was partially offset by impact of recent generic introductions, decreased COVID-19 vaccinations, diagnostic testing and over-the-counter (“OTC”) test kit sales, continued pharmacy reimbursement pressure and a decrease in store count.
Within the Health Care Benefits segment, the company registered revenues worth $26.75 billion in the second quarter, up 17.6% year over year driven by growth across all product lines.
Margin
Total cost (including Benefit Costs) rose 8.6% to $55.53 billion in the second quarter. Gross profit rose 12.9% to $35.38 billion. The gross margin expanded 92 basis points (bps) to 39.8%.
The adjusted operating margin in the quarter under review contracted 188 bps to 15.3% on a 24.5% rise in operating expenses to $21.78 billion.
2023 Guidance
CVS Health restated its adjusted EPS guidance for full-year 2023 to the band of $8.50-$8.70 from $8.70 to $8.90. The Zacks Consensus Estimate for 2023 earnings is pegged at $8.60.
The company has reiterated its full-year operating cash flow projection in the range of $12.5 billion to $13.5 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
VGM Scores
At this time, CVS Health has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CVS Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Down 12.3% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for CVS Health (CVS - Free Report) . Shares have lost about 12.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is CVS Health due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
CVS Health Q2 Earnings Surpass Estimates, Margins Up
CVS Health second-quarter 2023 adjusted earnings per share of $2.21 declined 12.6% year over year but exceeded the Zacks Consensus Estimate by 4.3%.
The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale, and other adjustments.
On a reported basis, the company’s GAAP earnings were $1.48 per share, down 35.4% year over year.
Total revenues in the second quarter rose 10.3% year over year to $88.92 billion. The top line also beat the Zacks Consensus Estimate by 2.5%.
Quarter in Detail
The company recently realigned the composition of its segments. It created the Health Services segment (comprising the company’s pharmacy benefit management operations, health care services and provider enablement solutions) and the Pharmacy & Consumer Wellness segment (comprising enterprise pharmacy fulfilment and retail front store operations).
Health Services revenues were up 7.6% to $46.22 billion in the reported quarter. The upside was primarily driven by pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health, partially offset by continued client price improvements.
Total pharmacy claims processed fell 1.2% on a 30-day equivalent basis, reflecting an expected Medicaid customer contract change and a decrease in COVID-19 vaccinations. The decline was largely offset by net new business.
Revenues from CVS Health’s Pharmacy & Consumer Wellness segment were up 7.6% year over year to $28.78 billion. The impressive growth was driven by increased prescription and front store volume, pharmacy drug mix and brand inflation. However, this growth was partially offset by impact of recent generic introductions, decreased COVID-19 vaccinations, diagnostic testing and over-the-counter (“OTC”) test kit sales, continued pharmacy reimbursement pressure and a decrease in store count.
Within the Health Care Benefits segment, the company registered revenues worth $26.75 billion in the second quarter, up 17.6% year over year driven by growth across all product lines.
Margin
Total cost (including Benefit Costs) rose 8.6% to $55.53 billion in the second quarter. Gross profit rose 12.9% to $35.38 billion. The gross margin expanded 92 basis points (bps) to 39.8%.
The adjusted operating margin in the quarter under review contracted 188 bps to 15.3% on a 24.5% rise in operating expenses to $21.78 billion.
2023 Guidance
CVS Health restated its adjusted EPS guidance for full-year 2023 to the band of $8.50-$8.70 from $8.70 to $8.90. The Zacks Consensus Estimate for 2023 earnings is pegged at $8.60.
The company has reiterated its full-year operating cash flow projection in the range of $12.5 billion to $13.5 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
VGM Scores
At this time, CVS Health has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CVS Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.